BR9912104A - Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratamento de um mamìfero, que sofra de inflamação patológica e autoimunidade - Google Patents
Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratamento de um mamìfero, que sofra de inflamação patológica e autoimunidadeInfo
- Publication number
- BR9912104A BR9912104A BR9912104-2A BR9912104A BR9912104A BR 9912104 A BR9912104 A BR 9912104A BR 9912104 A BR9912104 A BR 9912104A BR 9912104 A BR9912104 A BR 9912104A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- autoimmunity
- pharmaceutical compositions
- fluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 6
- 206010061218 Inflammation Diseases 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 3
- 230000005784 autoimmunity Effects 0.000 title abstract 3
- 230000004054 inflammatory process Effects 0.000 title abstract 3
- 230000001575 pathological effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000002892 organic cations Chemical class 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS, COMPOSIçõES FARMACêUTICAS, PROCESSO PARA A MANUFATURA DE UM COMPOSTO, E, MéTODO DE TRATAMENTO DE UM MAMìFERO, QUE SOFRA DE INFLAMAçãO PATOLóGICA E AUTOIMUNIDADE" A invenção refere-se a compostos da fórmula geral (I) em que R é Me, Et, n-Pr, iso-Pr, n-Bu, iso-Bu, sec-Bu ou alila; R' é hidrogênio, Me, MeO, fluoro, cloro, bromo, CF~ 3~ ou OCH~ x~F~ y~; R" é hidrogênio ou fluoro, com a condição de que R" seja fluoro quando R' for fluoro; e adicionalmente quando R' e R" forem ambos hidrogênio, R não seja Me; R~ 4~ é selecionado a partir de hidrogênio e cátions orgânicos e inorgânicos farmacêuticamente aceitáveis; R~ 5~ é selecionado a partir de MeS, EtS, n-PrS, iso-PrS, MeSO, EtSO, MeSO~ 2~ e EtSO~ 2~; em que x = 0-2, y= 1-3, com a condição de que x + y = 3; e Me é metila, Et é etila, Pr é propila e Bu é butila; e qualquer tautómero, isómero ótico ou racemato dos mesmos. A invenção refere-se também composições farmacêuticas, que contêm um composto de fórmula geral (I), junto com um veículo farmacêuticamente aceitável. Estão também incluídos métodos para a preparação dos compostos de fórmula (I), assim como métodos para o tratamento de mamíferos, que sofram de doenças resultantes de autoimunidade e inflamação patológica por administração de um composto tendo a fórmula (I) ao referido mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802550A SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Quinoline derivatives |
| PCT/SE1999/001271 WO2000003992A1 (en) | 1998-07-15 | 1999-07-14 | Quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9912104A true BR9912104A (pt) | 2001-05-02 |
| BR9912104B1 BR9912104B1 (pt) | 2010-07-13 |
Family
ID=20412094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9912104-2A BR9912104B1 (pt) | 1998-07-15 | 1999-07-14 | compostos derivados de quinolina, composições farmacêuticas, e, processo para a manufatura de um composto. |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1097139B1 (pt) |
| JP (1) | JP4082865B2 (pt) |
| KR (1) | KR100551611B1 (pt) |
| CN (1) | CN1114597C (pt) |
| AP (1) | AP1425A (pt) |
| AT (1) | ATE229005T1 (pt) |
| AU (1) | AU745915B2 (pt) |
| BR (1) | BR9912104B1 (pt) |
| CA (1) | CA2334718C (pt) |
| DE (1) | DE69904333T2 (pt) |
| DK (1) | DK1097139T3 (pt) |
| EE (1) | EE04276B1 (pt) |
| ES (1) | ES2187176T3 (pt) |
| HR (1) | HRP20010038A2 (pt) |
| HU (1) | HUP0103634A3 (pt) |
| ID (1) | ID27547A (pt) |
| IL (1) | IL140009A0 (pt) |
| IS (1) | IS2187B (pt) |
| NO (1) | NO317545B1 (pt) |
| NZ (1) | NZ508924A (pt) |
| OA (1) | OA11580A (pt) |
| PL (1) | PL200147B1 (pt) |
| PT (1) | PT1097139E (pt) |
| RU (1) | RU2213734C2 (pt) |
| SE (1) | SE9802550D0 (pt) |
| TR (1) | TR200100086T2 (pt) |
| UA (1) | UA70944C2 (pt) |
| WO (1) | WO2000003992A1 (pt) |
| YU (1) | YU1401A (pt) |
| ZA (1) | ZA200007493B (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| ATE430745T1 (de) | 2000-10-12 | 2009-05-15 | Merck & Co Inc | Aza- und polyaza naphthalenyl karboxamide als inhibitoren der hiv-integrase |
| AU1532802A (en) | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| AU2003218130A1 (en) | 2002-03-15 | 2003-09-29 | Merck And Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| SG10201508623RA (en) | 2005-10-19 | 2015-11-27 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| WO2009082471A1 (en) | 2007-12-20 | 2009-07-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| MX2011002033A (es) | 2008-09-03 | 2011-05-02 | Teva Pharma | 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune. |
| ES2564931T3 (es) | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| CA2771203C (en) | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| MX2012010066A (es) | 2010-03-03 | 2012-10-03 | Teva Pharma | Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato. |
| WO2011109526A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus nephritis using laquinimod |
| CN104610144A (zh) | 2010-07-09 | 2015-05-13 | 泰华制药工业有限公司 | 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途 |
| KR20130065728A (ko) | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| EP2970129A2 (en) | 2013-03-14 | 2016-01-20 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| AU2021275994A1 (en) * | 2020-05-21 | 2022-12-22 | Stemsynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| DE4120646A1 (de) * | 1991-06-22 | 1992-12-24 | Bayer Ag | 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate |
| SE469368B (sv) * | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
| CN1063686A (zh) * | 1992-03-12 | 1992-08-19 | 华西医科大学药物研究所 | 用活性酯法合成维司力农 |
| SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
| JPH07224040A (ja) * | 1994-02-07 | 1995-08-22 | Fujisawa Pharmaceut Co Ltd | キノリン誘導体 |
| GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
| SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
| SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
| GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-07-15 SE SE9802550A patent/SE9802550D0/xx unknown
-
1999
- 1999-07-14 AP APAP/P/2001/002040A patent/AP1425A/en active
- 1999-07-14 AU AU50775/99A patent/AU745915B2/en not_active Ceased
- 1999-07-14 NZ NZ508924A patent/NZ508924A/xx not_active IP Right Cessation
- 1999-07-14 HR HR20010038A patent/HRP20010038A2/hr not_active Application Discontinuation
- 1999-07-14 UA UA2000127137A patent/UA70944C2/uk unknown
- 1999-07-14 EE EEP200100007A patent/EE04276B1/xx not_active IP Right Cessation
- 1999-07-14 CN CN99808597A patent/CN1114597C/zh not_active Expired - Fee Related
- 1999-07-14 JP JP2000560099A patent/JP4082865B2/ja not_active Expired - Fee Related
- 1999-07-14 DK DK99935261T patent/DK1097139T3/da active
- 1999-07-14 PT PT99935261T patent/PT1097139E/pt unknown
- 1999-07-14 YU YU1401A patent/YU1401A/sh unknown
- 1999-07-14 IL IL14000999A patent/IL140009A0/xx not_active IP Right Cessation
- 1999-07-14 OA OA1200100012A patent/OA11580A/en unknown
- 1999-07-14 ES ES99935261T patent/ES2187176T3/es not_active Expired - Lifetime
- 1999-07-14 CA CA002334718A patent/CA2334718C/en not_active Expired - Fee Related
- 1999-07-14 EP EP99935261A patent/EP1097139B1/en not_active Expired - Lifetime
- 1999-07-14 DE DE69904333T patent/DE69904333T2/de not_active Expired - Lifetime
- 1999-07-14 ID IDW20010360A patent/ID27547A/id unknown
- 1999-07-14 WO PCT/SE1999/001271 patent/WO2000003992A1/en not_active Ceased
- 1999-07-14 RU RU2001104344/04A patent/RU2213734C2/ru not_active IP Right Cessation
- 1999-07-14 PL PL345389A patent/PL200147B1/pl unknown
- 1999-07-14 BR BRPI9912104-2A patent/BR9912104B1/pt not_active IP Right Cessation
- 1999-07-14 HU HU0103634A patent/HUP0103634A3/hu unknown
- 1999-07-14 TR TR2001/00086T patent/TR200100086T2/xx unknown
- 1999-07-14 AT AT99935261T patent/ATE229005T1/de not_active IP Right Cessation
- 1999-07-14 KR KR1020007014281A patent/KR100551611B1/ko not_active Expired - Fee Related
-
2000
- 2000-12-05 IS IS5753A patent/IS2187B/is unknown
- 2000-12-14 ZA ZA200007493A patent/ZA200007493B/en unknown
-
2001
- 2001-01-12 NO NO20010210A patent/NO317545B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA70944C2 (uk) | Похідні хіноліну, спосіб їх одержання, фармацевтична композиція та лікарський засіб на їх основі | |
| BR9909925A (pt) | Compostos, composições farmacêuticas, e, processos para a fabricação de um composto, e de tratamento de um mamìfero sofrendo de doenças resultantes da autoimunidade e inflamação patológica | |
| BR9912109A (pt) | Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratar um mamìfero sofrendo de inflamação patológica e autoimunidade | |
| BRPI9909282A (pt) | compostos de éter aminociclohexílicos e usos dos mesmos. | |
| MX9300141A (es) | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
| WO1996023489A3 (de) | Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen | |
| ES2061252T3 (es) | Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| MXPA03006855A (es) | Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion. | |
| DE69616749D1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
| BG105880A (en) | Compounds useful as anti-inflammatory agents | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BR0009651A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas | |
| BR0213040A (pt) | Composto, processo para preparar um composto, e, método de tratar doenças | |
| BR9813811A (pt) | "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo" | |
| BR9205640A (pt) | Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| ES2100222T3 (es) | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. | |
| ES2171889T3 (es) | Agente que reduce el colesterol en suero. | |
| BG101896A (en) | Pyrrolidinylhydroxamic acid compounds and method for their preparation | |
| ATE415965T1 (de) | Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung | |
| DE69420832D1 (de) | Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8 | |
| CY1105721T1 (el) | Δερματικοι αναισθητικοι παραγοντες | |
| ATE232387T1 (de) | Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes | |
| DK0865271T4 (da) | Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/07/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2314 DE 12-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |